

# German Ott

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1432576/german-ott-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145  
papers

22,574  
citations

58  
h-index

150  
g-index

155  
ext. papers

25,979  
ext. citations

7.5  
avg, IF

5.55  
L-index

#	Paper	IF	Citations
145	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1937-47	59.2	2971
144	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , <b>2004</b> , 103, 275-82	2.2	2955
143	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , <b>2010</b> , 463, 88-92	50.4	1149
142	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , <b>2011</b> , 470, 115-9	50.4	1068
141	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1396-1407	59.2	780
140	A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 2419-30	59.2	776
139	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , <b>2003</b> , 3, 185-97	24.3	751
138	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 13520-5	11.5	746
137	Molecular diagnosis of Burkitt's lymphoma. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 2431-42	59.2	700
136	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3452-9	2.2	669
135	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. <i>Science</i> , <b>2008</b> , 319, 1676-9	33.3	660
134	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , <b>2012</b> , 490, 116-20	50.4	600
133	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5494-502	12.9	507
132	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , <b>2014</b> , 123, 1214-7	2.2	404
131	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2013</b> , 121, 2253-63	2.2	393
130	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18250-5	11.5	377
129	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 200-7	2.2	360

128	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1111-1122	21.7	347
127	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , <b>2005</b> , 106, 3183-90	2.2	304
126	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , <b>2005</b> , 106, 4315-21	2.2	279
125	Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. <i>British Journal of Haematology</i> , <b>2005</b> , 131, 29-38	4.5	254
124	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 961-8	2.2	238
123	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. <i>Blood</i> , <b>1999</b> , 94, 3265-3268	2.2	238
122	Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. <i>Blood</i> , <b>2002</b> , 99, 3806-12	2.2	227
121	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , <b>2013</b> , 122, 3165-8		208
120	Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. <i>Blood</i> , <b>2008</b> , 111, 2385-7	2.2	195
119	Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6364-9	2.2	159
118	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. <i>Blood</i> , <b>2010</b> , 116, 4916-25	2.2	148
117	Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1216-22	2.2	148
116	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. <i>Blood</i> , <b>2013</b> , 122, 3884-91	2.2	143
115	Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2515-2526	2.2	137
114	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , <b>2009</b> , 114, 826-34	2.2	136
113	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1065-72	12.9	127
112	Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. <i>Haematologica</i> , <b>2014</b> , 99, 726-35	6.6	125
111	Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. <i>Journal of Hematopathology</i> , <b>2009</b> , 2, 103-11	0.4	122

110	The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. <i>Blood</i> , <b>2006</b> , 107, 3407	2.2	121
109	Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. <i>Blood</i> , <b>2004</b> , 104, 795-801	2.2	119
108	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 2352-7	11.5	116
107	Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. <i>Haematologica</i> , <b>2011</b> , 96, 1327-34	6.6	114
106	Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1086-1094	6.7	114
105	High-grade B-cell lymphoma with and/or rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , <b>2018</b> , 131, 2060-2064	2.2	107
104	Differential diagnosis between classic Hodgkin lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. <i>American Journal of Surgical Pathology</i> , <b>1998</b> , 22, 1184-91	6.7	104
103	Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. <i>American Journal of Pathology</i> , <b>2004</b> , 165, 481-90	5.8	102
102	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. <i>Blood</i> , <b>2008</b> , 112, 1374-81	2.2	100
101	A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. <i>Blood</i> , <b>2009</b> , 113, 1053-61	2.2	96
100	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , <b>2014</b> , 123, 1681-90	2.2	87
99	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , <b>2015</b> , 125, 1137-45	2.2	87
98	A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 1473-6	6.7	87
97	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , <b>2016</b> , 128, 1101-11	2.2	76
96	MINCR is a MYC-induced lncRNA able to modulate MYCN transcriptional network in Burkitt lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E5261-70	11.5	75
95	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1668-1677	2.2	67
94	Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. <i>Blood</i> , <b>2017</b> , 130, 310-322	2.2	66
93	Prevalence of Epstein-Barr virus DNA in different T-cell lymphoma entities in a European population. <i>International Journal of Cancer</i> , <b>1992</b> , 51, 562-7	7.5	65

92	MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , <b>2011</b> , 118, 5550-8	2.2	63
91	The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>American Journal of Clinical Pathology</i> , <b>2011</b> , 135, 54-61	1.9	60
90	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3727-32	12.9	60
89	bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. <i>Journal of Pathology</i> , <b>1996</b> , 179, 238-42	9.4	60
88	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , <b>2018</b> , 132, 413-422	2.2	58
87	A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 27, 52-8	5	57
86	Chromatin conformation analysis of primary patient tissue using a low input Hi-C method. <i>Nature Communications</i> , <b>2018</b> , 9, 4938	17.4	55
85	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> ,	10.7	49
84	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , <b>2012</b> , 120, 2290-6	2.2	48
83	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 1322-30	6.7	45
82	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , <b>2017</b> , 130, 1819-1831	2.2	42
81	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. <i>Hematology American Society of Hematology Education Program</i> , <b>2013</b> , 2013, 575-83	3.1	40
80	TP53 mutation and survival in aggressive B cell lymphoma. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 1381-1388	7.5	39
79	Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>2006</b> , 45, 203-10	5	38
78	Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1661-4	6.7	37
77	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , <b>2017</b> , 129, 333-346	2.2	36
76	Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. <i>Genes Chromosomes and Cancer</i> , <b>1998</b> , 22, 114-21	5	36
75	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. <i>Haematologica</i> , <b>2009</b> , 94, 1569-80	6.6	35

74	Mutations of are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. <i>Blood</i> , <b>2017</b> , 130, 323-327	2.2	34
73	Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. <i>Laboratory Investigation</i> , <b>2001</b> , 81, 977-86	5.9	32
72	Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 871-887	4.5	31
71	A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?. <i>Genes Chromosomes and Cancer</i> , <b>1999</b> , 26, 210-4	5	30
70	Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 61-6	6.7	29
69	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. <i>Blood</i> , <b>2019</b> , 133, 962-966	2.2	29
68	Non-random integration of Epstein-Barr virus in lymphoblastoid cell lines. <i>Genes Chromosomes and Cancer</i> , <b>1993</b> , 8, 38-48	5	27
67	The heterogeneity of follicular lymphomas: from early development to transformation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 468, 127-39	5.1	25
66	Primary pulmonary synovial sarcoma: a rare primary pulmonary tumor. <i>Lung</i> , <b>2014</b> , 192, 211-4	2.9	23
65	Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. <i>Journal of Hematopathology</i> , <b>2009</b> , 2, 77-81	0.4	23
64	A modular transcriptome map of mature B cell lymphomas. <i>Genome Medicine</i> , <b>2019</b> , 11, 27	14.4	19
63	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , <b>2018</b> , 131, 226-235	2.2	19
62	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 112	22.4	19
61	Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 616-624	4.5	16
60	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. <i>Haematologica</i> , <b>2018</b> , 103, 1182-1190	6.6	15
59	Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in-situ hybridization. <i>PLoS ONE</i> , <b>2014</b> , 9, e95047	3.7	15
58	Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas. <i>Journal of Hematopathology</i> , <b>2009</b> , 2, 83-7	0.4	14
57	The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 391-394	4.5	13



56	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. <i>Leukemia</i> , <b>2020</b> , 34, 543-552	10.7	13
55	New targeted therapies for malignant lymphoma based on molecular heterogeneity. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 39-51	2.8	12
54	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , <b>2021</b> , 106, 2682-2693	6.6	12
53	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 717-20	1.9	11
52	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 557-561	4.5	11
51	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1213-1221	1.9	11
50	The impact of SOCS1 mutations in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 627-637	4.5	10
49	Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e002156	6	8
48	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , <b>2021</b> , 12, 5183	17.4	8
47	Tubular breast cancer. A retrospective study. <i>Anticancer Research</i> , <b>2014</b> , 34, 3647-56	2.3	8
46	A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 356-364	6.7	7
45	A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score. <i>Journal of Hematopathology</i> , <b>2009</b> , 2, 187-94	0.4	6
44	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , <b>2020</b> , 1134, 125-135	6.6	6
43	Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 373-383	4.5	6
42	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. <i>Haematologica</i> , <b>2020</b> , 105, 2667-2670	6.6	5
41	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e267-e277	14.6	5
40	Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease. <i>Inflammatory Intestinal Diseases</i> , <b>2019</b> , 3, 125-137	2.5	5
39	Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. <i>Journal of Hematopathology</i> , <b>2008</b> , 1, 85-95	0.4	4

38	Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF- $\kappa$ B signalling. <i>Oncotarget</i> , <b>2017</b> , 8, 89580-89594	3.3	4
37	Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem. <i>Anticancer Research</i> , <b>2018</b> , 38, 1585-1593	2.3	4
36	Interphase cytogenetics of glioblastoma and gliosarcoma <b>1994</b> , 88, 420		4
35	The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 150-160	7.5	4
34	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 133-145	5.1	4
33	bcl-1 REARRANGEMENT AND CYCLIN D1 PROTEIN EXPRESSION IN MANTLE CELL LYMPHOMA <b>1996</b> , 179, 238		4
32	The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 479, 575-583	5.1	3
31	Experience with telepathology in combination with diagnostic assistance systems in countries with restricted resources. <i>Journal of Telemedicine and Telecare</i> , <b>2020</b> , 26, 488-494	6.8	3
30	Late lung metastasis of primary endometrial cancer. <i>Memo - Magazine of European Medical Oncology</i> , <b>2012</b> , 5, 262-265	0.3	2
29	Mantle cell lymphoma <b>2001</b> , 154-167		2
28	Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 249-252	1.9	1
27	Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis. <i>Peritoneal Dialysis International</i> , <b>2014</b> , 34, 561-5	2.8	1
26	Differentiation of low-grade non-Hodgkin's lymphomas using paraffin sections by image processing. <i>Cytometry</i> , <b>1998</b> , 34, 75-81		1
25	PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2842-2842	4.2	1
24	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. <i>Methods in Molecular Biology</i> , <b>2019</b> , 41-73	1.4	1
23	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients $\geq$ 5 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , <b>2021</b> , 138, 3517-3517	2.2	0
22	Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study. <i>Blood</i> , <b>2019</b> , 134, 1589-1589	2.2	0
21	Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1107-1115	1.9	0



20	The broad and challenging landscape of extranodal lymphoproliferations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 476, 633-646	5.1	o
19	Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumours. <i>Histopathology</i> , <b>2021</b> , 78, 831-837	7.3	o
18	Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 430-4	4.5	
17	Central nervous system lymphoma <b>2001</b> , 200-214		
16	Gene expression profiling in lymphoid malignancies <b>2001</b> , 162-186		
15	Hodgkin's lymphoma <b>2001</b> , 89-110		
14	Pathology and cytogenetics <b>2001</b> , 12-18		
13	Follicular lymphoma <b>2001</b> , 111-125		
12	MALT lymphoma and other marginal zone lymphomas <b>2001</b> , 126-140		
11	Small lymphocytic lymphoma and its variants <b>2001</b> , 141-153		
10	Diffuse large B-cell lymphoma <b>2001</b> , 168-181		
9	Burkitt's and lymphoblastic lymphomas <b>2001</b> , 182-199		
8	T-cell lymphoma <b>2001</b> , 215-232		
7	Cutaneous lymphoma <b>2001</b> , 233-251		
6	Lymphoma in the immunosuppressed <b>2001</b> , 252-265		
5	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). <i>Blood</i> , <b>2020</b> , 136, 5-6	2.2	
4	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. <i>Blood</i> , <b>2004</b> , 104, 415-415	2.2	
3	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. <i>Blood</i> , <b>2018</b> , 132, 4096-4096	2.2	

- 2 Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. *Blood*, **2010**, 116, 2005-2005 2.2
- 1 Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN). *Blood*, **2011**, 118, 1656-1656 2.2